Evidence supports the routine use of low-dose aspirin (ASA) in the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM). This restriction is based on the hypothesis that ASA doses >100 mg somehow decreased ticagrelor’s benefit in the Platelet Inhibition and Patient Outcomes (PLATO) U.S. They noted that regular aspirin use—taking either a 325-mg tablet or an 81-mg tablet two or more times per week—was associated with a 3% reduction in cancers over all, although they saw no effect on major cancers like those of the breast, prostate, or lung. Patients who consented were administered a standardized oral telephone survey regarding aspirin use. Gosk-Bierska I, Adamiec R, Doskocz W, et al. After the RCT, the treating physician decided whether to administer aspirin. 71.5%, P = 0.018) than subjects who maintained or gained weight during follow-up.
ASA and rofecoxib, that significantly suppressed the mucosal prostaglandin (PG) E(2) generation